Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was d...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.744085/full |
| _version_ | 1818569489552244736 |
|---|---|
| author | Nicolas Kerckhove Nicolas Kerckhove Nicolas Kerckhove Marie Selvy Céline Lambert Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Jérôme Busserolles Sophie Trévis Vincent Pinon Denis Pezet David Balayssac David Balayssac |
| author_facet | Nicolas Kerckhove Nicolas Kerckhove Nicolas Kerckhove Marie Selvy Céline Lambert Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Jérôme Busserolles Sophie Trévis Vincent Pinon Denis Pezet David Balayssac David Balayssac |
| author_sort | Nicolas Kerckhove |
| collection | DOAJ |
| description | Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management. |
| first_indexed | 2024-12-14T06:48:41Z |
| format | Article |
| id | doaj.art-2b597ee8a3434985a82d29f25ae2a813 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T06:48:41Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-2b597ee8a3434985a82d29f25ae2a8132022-12-21T23:12:58ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-11-011210.3389/fphar.2021.744085744085Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral NeuropathyNicolas Kerckhove0Nicolas Kerckhove1Nicolas Kerckhove2Marie Selvy3Céline Lambert4Coralie Gonneau5Gabrielle Feydel6Caroline Pétorin7Agnès Vimal-Baguet8Sergey Melnikov9Sharif Kullab10Mohamed Hebbar11Olivier Bouché12Florian Slimano13Vincent Bourgeois14Valérie Lebrun-Ly15Frédéric Thuillier16Thibault Mazard17David Tavan18Kheir Eddine Benmammar19Brigitte Monange20Mohamed Ramdani21Denis Péré-Vergé22Floriane Huet-Penz23Ahmed Bedjaoui24Florent Genty25Cécile Leyronnas26Jérôme Busserolles27Jérôme Busserolles28Sophie Trévis29Vincent Pinon30Denis Pezet31David Balayssac32David Balayssac33INSERM U1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, FranceDélégation à La Recherche Clinique et à L’Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, FranceInstitut Analgesia, Université Clermont Auvergne, Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, FranceDélégation à La Recherche Clinique et à L’Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, FranceDélégation à La Recherche Clinique et à L’Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, FranceService Oncologie Digestive, CHU Clermont-Ferrand, Clermont-Ferrand, FranceService Oncologie Digestive, CHU Clermont-Ferrand, Clermont-Ferrand, FranceService Chirurgie Générale et Viscérale, Centre Hospitalier de Saint-Flour, Saint-Flour, FranceService Oncologie, Centre Hospitalier de Moulins Yzeure, Moulins, FranceCHRU Lille, Service Oncologie, Lille, FranceService Oncologie Digestive, CHU Reims, Université de Reims Champagne-Ardenne, Reims, FranceService Pharmacie, CHU Reims, BioSpect, SFR CAP-Santé, Université de Reims Champagne-Ardenne, Reims, France0Service Oncologie Digestive, Centre Hospitalier de Boulogne sur Mer, Boulogne-Sur-Mer, France1Service Oncologie, CHU Limoges, Limoges, France1Service Oncologie, CHU Limoges, Limoges, France2IRCM, Inserm, Univ Montpellier, ICM, Montpellier, France3Service Gastro-entérologie, Infirmerie Protestante de Lyon, Caluire et Cuire, France4Service Oncologie, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France4Service Oncologie, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France5Service Gastro-entérologie, Centre Hospitalier de Béziers, Béziers, France6Service Hépato-gastro-entérologie, Centre Hospitalier Saint-Joseph Saint-Luc, Lyon, France7Service Gastro Entérologie, Centre Hospitalier Alpes Leman, Contamine sur Arve, France8Service Gastro-entérologie, Centre Hospitalier Intercommunal Les Hôpitaux Du Léman, Thonon Les Bains, France9Service Chirurgie Digestive et Viscérale, Centre Hospitalier de Vichy, Vichy, France0Service Oncologie, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, FranceInstitut Analgesia, Université Clermont Auvergne, Clermont-Ferrand, France1Service Pharmacie, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont-Ferrand, France1Service Pharmacie, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont-Ferrand, France2INSERM, M2iSH, USC-INRA 2018, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, FranceDélégation à La Recherche Clinique et à L’Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, FranceOxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.https://www.frontiersin.org/articles/10.3389/fphar.2021.744085/fullchemotherapy-induced peripheral neuropathyneuropathic paincolorectal canceroxaliplatincluster analysis |
| spellingShingle | Nicolas Kerckhove Nicolas Kerckhove Nicolas Kerckhove Marie Selvy Céline Lambert Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Jérôme Busserolles Sophie Trévis Vincent Pinon Denis Pezet David Balayssac David Balayssac Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy Frontiers in Pharmacology chemotherapy-induced peripheral neuropathy neuropathic pain colorectal cancer oxaliplatin cluster analysis |
| title | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy |
| title_full | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy |
| title_fullStr | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy |
| title_full_unstemmed | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy |
| title_short | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy |
| title_sort | colorectal cancer survivors suffering from sensory chemotherapy induced peripheral neuropathy are not a homogenous group secondary analysis of patients profiles with oxaliplatin induced peripheral neuropathy |
| topic | chemotherapy-induced peripheral neuropathy neuropathic pain colorectal cancer oxaliplatin cluster analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.744085/full |
| work_keys_str_mv | AT nicolaskerckhove colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT nicolaskerckhove colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT nicolaskerckhove colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT marieselvy colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT celinelambert colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT coraliegonneau colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT gabriellefeydel colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT carolinepetorin colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT agnesvimalbaguet colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT sergeymelnikov colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT sharifkullab colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT mohamedhebbar colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT olivierbouche colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT florianslimano colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT vincentbourgeois colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT valerielebrunly colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT fredericthuillier colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT thibaultmazard colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT davidtavan colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT kheireddinebenmammar colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT brigittemonange colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT mohamedramdani colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT denispereverge colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT florianehuetpenz colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT ahmedbedjaoui colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT florentgenty colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT cecileleyronnas colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT jeromebusserolles colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT jeromebusserolles colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT sophietrevis colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT vincentpinon colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT denispezet colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT davidbalayssac colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy AT davidbalayssac colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy |